Dr. Ruan Discusses Biomarkers in MCL

Jia Ruan, MD, PhD
Published: Monday, Mar 19, 2018



Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma (MCL).

One of the challenges that persists in the treatment of patients with MCL is selection for therapies. Ruan says biomarkers need to be identified to predict risk or responsiveness to agents or combinations of agents. This would require an additional and concerted effort, Ruan says, and would be best investigated in a prospective clinical trial.

Ruan suggests that collecting clinical, pathological, and biomarker data in a prospective clinical trial could subsequently lead to more specific treatment regimens for patients with MCL.
 


Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma (MCL).

One of the challenges that persists in the treatment of patients with MCL is selection for therapies. Ruan says biomarkers need to be identified to predict risk or responsiveness to agents or combinations of agents. This would require an additional and concerted effort, Ruan says, and would be best investigated in a prospective clinical trial.

Ruan suggests that collecting clinical, pathological, and biomarker data in a prospective clinical trial could subsequently lead to more specific treatment regimens for patients with MCL.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x